InMed Pharmaceuticals reported QQ3 2024 results reflecting a modest top-line increment on a YoY basis but an ongoing cash burn typical of a clinical-stage biotech. Revenue rose to USD 1.17 million (+13.4% YoY; -5.5% QoQ) with a gross margin of 11.9% (USD 139k gross profit). The company remains loss-making, delivering an EBITDA of -USD 2.36 million and a net income of -USD 1.72 million for the quarter, translating to earnings per share of -0.24. Research and development spend remained the primary driver of operating expenses, supporting the pipeline strategy around INM755 (topical cream for epidermolysis bullosa), INM088 (preclinical for glaucoma), and INM405 (pain).